A gist on an obscure neoplasm in Ghana: gastrointestinal stromal tumours.
Gastrointestinal stromal tumours
Imatinib
Partial gastrectomy
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
received:
10
05
2023
accepted:
24
10
2023
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
epublish
Résumé
Gastrointestinal Stromal Tumour is a rare but potentially curable tumour of the gastrointestinal tract accounting for up to 1% of all gastrointestinal tumours. The discovery of Imatinib mesylate, a novel tyrosine kinase inhibitor has improved the chances even for unresectable, recurrent, or metastatic diseases. This study sought to document the clinical and pathological characteristics of GISTs from two tertiary hospitals in Ghana that have undergone immunohistochemistry confirmation between 2014 and 2021. The median age of the subjects was 50 years with most of them (28.0%) being above 61 years. There were more females than males (64.0% vs. 36.0%). Abdominal mass and abdominal pain made up the majority of the clinical presentations. The majority of the subjects had partial gastrectomy (32.0%) which was followed by wedge resection (28.0%). Appendectomy and sleeve gastrectomy were the least performed procedures (8% each). Four of the 25 patients (16.0%) had resections of involved contiguous organs done with splenectomy being the most common procedure. The majority of GISTs were found in the stomach (68.0%) followed by the appendix (12.0%) and small bowel (12.0%). Gastrointestinal bleeding (55.8%) and abdominal pain (38.5%) were the most reported symptoms. Free resection margins were observed in 84.0% of the subjects and only 3/25 (12.0%) experienced tumour recurrence. GIST is a potentially curable tumour that once was obscure but currently gaining popularity. Surgical resection offers the hope of a cure for localized disease while targeted therapies is a viable option for recurrent, metastatic, or unresectable tumours.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal Stromal Tumour is a rare but potentially curable tumour of the gastrointestinal tract accounting for up to 1% of all gastrointestinal tumours. The discovery of Imatinib mesylate, a novel tyrosine kinase inhibitor has improved the chances even for unresectable, recurrent, or metastatic diseases.
METHODS
METHODS
This study sought to document the clinical and pathological characteristics of GISTs from two tertiary hospitals in Ghana that have undergone immunohistochemistry confirmation between 2014 and 2021.
RESULTS
RESULTS
The median age of the subjects was 50 years with most of them (28.0%) being above 61 years. There were more females than males (64.0% vs. 36.0%). Abdominal mass and abdominal pain made up the majority of the clinical presentations. The majority of the subjects had partial gastrectomy (32.0%) which was followed by wedge resection (28.0%). Appendectomy and sleeve gastrectomy were the least performed procedures (8% each). Four of the 25 patients (16.0%) had resections of involved contiguous organs done with splenectomy being the most common procedure. The majority of GISTs were found in the stomach (68.0%) followed by the appendix (12.0%) and small bowel (12.0%). Gastrointestinal bleeding (55.8%) and abdominal pain (38.5%) were the most reported symptoms. Free resection margins were observed in 84.0% of the subjects and only 3/25 (12.0%) experienced tumour recurrence.
CONCLUSION
CONCLUSIONS
GIST is a potentially curable tumour that once was obscure but currently gaining popularity. Surgical resection offers the hope of a cure for localized disease while targeted therapies is a viable option for recurrent, metastatic, or unresectable tumours.
Identifiants
pubmed: 37932827
doi: 10.1186/s13104-023-06593-8
pii: 10.1186/s13104-023-06593-8
pmc: PMC10629135
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318Informations de copyright
© 2023. The Author(s).
Références
Cureus. 2019 Feb 22;11(2):e4120
pubmed: 31037234
J Egypt Natl Canc Inst. 2012 Mar;24(1):31-9
pubmed: 23587230
J Am Coll Surg. 2007 Sep;205(3):479-91 (Quiz 524)
pubmed: 17765165
Histopathology. 2010 Aug;57(2):259-70
pubmed: 20716168
Int J Surg. 2014;12(4):269-80
pubmed: 24530605
Langenbecks Arch Surg. 2006 Aug;391(4):322-9
pubmed: 16402273
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78
pubmed: 29846513
Semin Diagn Pathol. 2006 May;23(2):70-83
pubmed: 17193820
World J Surg Oncol. 2009 Aug 01;7:61
pubmed: 19646278
Cell Biochem Biophys. 2015 Dec;73(3):743-7
pubmed: 27259319
BMC Public Health. 2020 Jun 19;20(1):962
pubmed: 32560711
World J Clin Cases. 2020 Aug 6;8(15):3142-3155
pubmed: 32874969
World J Gastrointest Oncol. 2013 Jun 15;5(6):102-12
pubmed: 23847717
Am J Surg Pathol. 2003 May;27(5):625-41
pubmed: 12717247
Surgery. 2007 Jun;141(6):748-56
pubmed: 17560251
BMC Cancer. 2014 May 23;14:362
pubmed: 24884730
J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30
pubmed: 17624289
Ann Oncol. 2006 Sep;17 Suppl 10:x280-6
pubmed: 17018739
Afr Health Sci. 2011 Mar;11(1):134-8
pubmed: 21572869
Surg Oncol. 2014 Jun;23(2):92-8
pubmed: 24726745
Clin Sarcoma Res. 2017 Apr 21;7:6
pubmed: 28465823
Hum Pathol. 2002 May;33(5):459-65
pubmed: 12094370
World J Gastroenterol. 2018 May 14;24(18):1925-1941
pubmed: 29760538
Asia Pac J Clin Oncol. 2013 Mar;9(1):40-6
pubmed: 22897235
Pan Afr Med J. 2015 Oct 20;22:161
pubmed: 26893795
Cancer. 2005 Nov 1;104(9):1781-8
pubmed: 16136600
World J Surg Oncol. 2011 Feb 01;9:13
pubmed: 21284869